Cellectis (CLLS) Notes Payables (2014 - 2016)

Cellectis' (CLLS) quarterly Notes Payables came in at $2.1 million in Q1 2016, down 0.68% quarter-over-quarter from $2.1 million in Q4 2015.

Cellectis (CLLS) Notes Payables (2014 - 2016) Analysis & Trends

Cellectis' Notes Payables history runs 3 years deep, the most recent figure standing at $2.1 million for Q1 2016.

  • On a quarterly basis, Notes Payables changed N/A year-over-year to $2.1 million in Q1 2016; TTM through Mar 2016 was $2.1 million, a N/A change from a year earlier, with the FY2015 full-year figure at $2.1 million, up 86.22% from the prior year.
  • Notes Payables eased to $2.1 million in Q1 2016 per CLLS's latest filing, from $2.1 million in the prior quarter.
  • Across five years, Notes Payables topped out at $3.4 million in Q2 2015 and bottomed at $1.1 million in Q4 2014.
  • The 3-year median for Notes Payables is $2.1 million (2015), against an average of $2.4 million.
  • Biggest YoY gain for Notes Payables was 95.45% in 2015; the steepest drop was 95.45% in 2015.
  • Year by year, Notes Payables stood at $1.1 million in 2014, then jumped by 95.45% to $2.1 million in 2015, then slipped by 0.68% to $2.1 million in 2016.
  • Per Business Quant, the three latest CLLS Notes Payables figures stand at $2.1 million (Q1 2016), $2.1 million (Q4 2015), and $3.3 million (Q3 2015).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Cellectis 281.48 Mn 95.81 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2016 2.09 Mn
Dec 31, 2015 2.11 Mn
Sep 30, 2015 3.32 Mn
Jun 30, 2015 3.35 Mn
Dec 31, 2014 1.08 Mn